Fred Kadiddlehopper
2 days ago
Mahesh Krishnan Elected to Halozyme's Board of Directors
April 25 2024 - 4:45PM
PR Newswire (US)
Alert
Print
Share On Facebook
SAN DIEGO, April 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services.
"Mahesh is a dynamic and highly accomplished healthcare executive, and we are pleased to welcome him to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "His experience with building and growing business opportunities in addition to his medical expertise, will provide valuable perspective as we expand our leadership as the premier provider of innovative drug delivery technologies."
Dr. Krishnan currently serves as Group Vice President of Growth at DaVita, Inc., one of the largest providers of kidney care services in the U.S. He was co-lead of the DaVita Venture Group, where he oversaw strategic partnerships in technology and research and development within the organization. In his current role, he also oversees aspects of medical policy in Washington, D.C. Dr. Krishnan previously served as DaVita's Group Vice President of Research and Development and was the company's first international Chief Medical Officer. Prior to DaVita, he served in various roles at Amgen Inc., including as the Global Development Leader for Epogen® and Executive Director, Medical Policy for all of Amgen's domestic products. Prior to his time at Amgen, Dr. Krishnan was a practicing nephrologist at Virginia Nephrology Group.
"I am honored to join Halozyme as a board member at such an exciting time for their business," said Dr. Krishnan. "As they continue to innovate with their disruptive drug delivery technologies and execute their patient centric vision, I look forward to leveraging my background and sharing my expertise to support their growth."
Dr. Krishnan earned his B.S. in pre-medicine from The Pennsylvania State University and M.D. from Jefferson Medical College at Thomas Jefferson University. He also holds an M.P.H. from Johns Hopkins University and an M.B.A. in healthcare management from the Johns Hopkins Carey School of Business.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of reducing treatment burden for patients. Having touched more than 800,000 patient lives in post-marketing use in seven commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.
For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.
easycomeandgo
2 days ago
Look, the market is weak, no matter how much encouraging word is put out about the economy. Inflation is persistent, which is hardly surprising in view of crazy spending in order to buy the election. The no new taxes for under $400 thousand earners is likewise rubbish, as inflation is a hidden tax impacting all, low earners especially. Bidenamics is not a good thing. I am not saying that Trump is a good thing in other ways. Having said all that, what one shareholder thinks Halozyme stock “should” do is immaterial. The stock does what it does regardless of the “should”s. Institutions holding most of the stock are not idiots, if it were so cheap and should go up, they would buy and it would go up. There is more to this story, way more, that this message board doesn’t know or doesn’t say. Management more than likely knows the rest of the story, but doesn’t say. It doesn’t serve them to say. This stock is out in the wilderness, only a fool buys it blindly. Not enough fools, surprisingly, at least not Halozyme wanting fools.
easycomeandgo
4 days ago
Probably not verbatim: “I want you to get out of your chairs, open the window and holler, I’m as mad as hell… and I’m not gonna take this any more!!! “
That precisely what I did when I sold half my position at below $40 instead of the 45 I was aiming for. (Dumb luck, it worked out.)
JPM/Jamie Dimon not very positive on this market. So far, Jamie has been more correct than not. As far as Halozyme goes, we cannot say the same for the analysts. But then, they are just a cog in the marketing machine. Thank Heaven, it has been a pretty good annual source of moolah for some management figures, that is for certain.
Fred Kadiddlehopper
5 days ago
I share your frustration with this management team. The BOD is asleep at the wheel or somehow beholden to Helen and unwilling to act. Evidently, she is very adept at shoring up her flanks preserving her internal power, yet a dismal failure at making profitable commercial deals. I'm at a loss as to how a multi-billion dollar company can drift into paralysis like this, but it seems that there is no answer on the visible horizon. We shareholders are getting more wise to the fact that the Empress has no clothes, and I'd expect that it is also becoming more widely understood as each week goes by. What the consequence of that will be is very uncertain from where I sit, but the PPS is bound to drift lower with each passing week until something changes.
stockrafter
6 days ago
Mr Kadidlehopper........
"Do you think it possible that Halozyme is simply selling the rhuph20 as a commodity without a partnership deal"
Not an expert on the matter, but see no reason why they couldn't for preliminary studies, heck give it to them for preliminary work, but would suspect a deal would need to be made before any clinical trial, for legal reasons.
At this point, really tired of this company. Thought ATRS was bad at PR, but this is crazy. So much going on yet so little information from the company.
Still waiting for the New Fancy 10 ml injector patent filing to be posted. Helen mentioned it more than a year ago, and a filing needs to get posted before any public trial can be conducted.
Still waiting for additional use of any of the injectors. Both ATRS and HALO mention products that could be developed like Xyosted, but nothing. Internal products are something HALO controls and could discuss the progress. Several patent filings show several potential products.
Still waiting for new Enhanze deals, as many others have mentioned....
Still waiting for info on the two products I posted on with hard facts......
Still waiting, and waiting, for the SP to go above and stay above average buy price....but there it goes down again at this time......
stockrafter
1 week ago
biotech....."What clues have seen you for Selatogrel being used with rhuph20?"
Absolutely none at all......But if you read a past post you would know Halo gets low to double digit for supplying the....AutoInjector... and...Packaging...the Selatogrel product.....of which thousands are being cranked out for the growing on going clinical trial...........around 10-14 percent royalties of a blockbuster product is worth at least mentioning on the website or in a presentation once in awhile......
See past post on a comment from an old ATRS presentation........"SUPPLY fully packaged product at cost plus margin and ROYALTIES escalating to low double digits".............which answer's Jeff's comment on Yahoo.......The AI business has huge potential if it could combine drug-rhuph20-AI-packaging for any of the blockbuster bio drugs......not low signal digits.....but mid-teen royalties.....
Fred...."In my opinion, if HALO has contracts with these companies, this is material information that must be disclosed to the general investing public."
They are both hidden in the corners of Halo documents, but terribly under reported in any Halo presentations..........
Halo involved in two products that have blockbuster potential, per both of the product companies, and not a peep from Halo.......Therefore a share price of 38 bucks......IMO....
biotechinvestor1
1 week ago
Roche subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
04/17/2024 | Briefing.com
RHHBY
Roche announced today data from the Phase Ill
OCARINA Il study (S31.006) of OCREVUS (ocrelizumab), an investigational twice-yearly, 10-minute subcutaneous (SC) injection. Results showed near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis (RMS or PPMS) which reinforce the potential benefits of this investigational formulation. Treatment with OCREVUS SC led to rapid and sustained B-cell depletion in the blood. The data will be presented as an oral presentation at the 76th American Academy of Neurology (AAN) Annual Meeting taking place April 13-18 in Denver and has been recognised as an abstract of distinction by the AAN scientific committee. Updated, longer-term results showed that OCREVUS SC injection (920 mg; n=236; both treatment arms [OCR SC/SC and OCR IV/SC]) resulted in near-complete suppression of relapse activity (97.2% had no relapse during the treatment phase) and MRI up to 48 weeks with an ARR of 0.04, and most patients having no T1 gadolinium-enhancing (T1 Gd+) lesions and no new/enlarging T2 lesions. These lesion types are markers of active inflammation and burden of disease, respectively.
easycomeandgo
3 weeks ago
Hmmmm… Come on “doom and gloom” brothers, a little more vigorous efforts, if you please. More gloom, Scotty, this thing needs help to achieve warp gains. We have pumpers on the starboard bow, life, yes…, but not as we know it, jinxing the good ship Halozyme. Oh, I almost forgot about the market tanking. Does THAT make any difference? Why? Are we in unfriendly territory, neutralizing the salutary doom and gloom efforts?
Fred Kadiddlehopper
3 weeks ago
I would add that the cup and handle formation is also a bullish indicator, FWIW. All I see, though is a stock locked in a very clear, definable pattern, and on the high end of that pattern at that; so, absent news, this is likely going to sag to the mid to low 30s IMHO.
maumar
3 weeks ago
Halozyme Therapeutics Inc forms bullish "Double Moving Average Crossover" chart pattern
Apr 08, 2024
Trading Central has detected a "Double Moving Average Crossover" chart pattern formed on Halozyme Therapeutics Inc (HALO:NASDAQ). This bullish signal indicates that the stock price may rise from the close of $39.91.
Tells Me: The price is generally in an established trend (bullish or bearish) for the time horizon represented by the moving average periods.
Moving averages (MA) are used to smooth out the volatility or "noise" in the price series, to make it easier to discover the underlying trend. By plotting the average price over the last several bars, the line is less "jerky" than plotting the actual prices. In the double crossover method, a bullish event is generated when a faster moving average crosses above a slower moving average (21-bar MA crosses 50-bar, or 50-bar MA crosses 200-bar). In this state, the price is likely in an established uptrend. The opposite is true when the faster slips below the slower moving average, triggering a bearish event.
This bullish pattern can be seen on the following chart and was detected by Trading Central proprietary pattern recognition technology.
I actually think the crossover happened today but the article is from yesterday. According to yahoo finance, the 50 is at $38.74 and the 200 at $38.66. Hopefully, some good news is around the corner.
https://finance.yahoo.com/quote/HALO/chart?nn=1#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--
biotechinvestor1
3 weeks ago
The top 5 science research-related stocks in 2024, as of the latest data available, are:
Biomarin Pharmaceuticals Inc. (BMRN) - 43.0% 5-Year Average Annual EPS Forecast
Halozyme Therapeutics, Inc. (HALO) - 25.0% 5-Year Average Annual EPS Forecast
Incyte Corporation (INCY) - 22.5% 5-Year Average Annual EPS Forecast
Genmab AS (GMAB) - 19.7% 5-Year Average Annual EPS Forecast
Exelixis, Inc. (EXEL) - 19.0% 5-Year Average Annual EPS Forecast
These stocks were chosen based on their forecasted earnings growth over the next five years, with a focus on those expected to grow EPS by an average of at least 9.5% per year over the next five years.
easycomeandgo
4 weeks ago
Oh, go take a hike! Do you really believe I am going to scour the board for my old posts just to obey your frivolous quibbles? Do you realize how goofy you sound?I tell you this much, since I looked, the shares I bought below 34 I bought on 06/06/23. The ones I sold just below 40 I bought earlier, around the same price or less. Don’t worry, I have already settled with the IRS. If that isn’t enough for you, too bad.
OK, I looked. On 06/07/23 I posted:
“After posting my reservations about this company, many of which remain, I think it is only proper to note that yesterday I picked up some shares. I didn’t bet the farm, I don‘t do that any more on any stock, but did pick up a few thousand shares. I hope that the downside is limited, but I don’t know what my upside hopes are as the company has been utterly mute. Definitely not “to the Moon, Alice”. I expect to take half off the table in the mid 40’s, as things now appear.”
Now, take a hike!
easycomeandgo
4 weeks ago
Since I mentioned prices, I went to my brokerage account to check. Of the shares I now own I bought 20% below 34; 40% below 35; and 40% below 38. Not proud of that last 40%. I sold half just below 40 (did not hold to 45 as I first planned to). Those share I bought earlier than the ones I now own, so I probably averaged below 34 for them. “Yeah, right.” Not that it makes much difference, my position in Halozyme is small compared to the old days. With what I have, I am just waiting to go long term. What I sold was short term, unfortunately, but I had had enough.
easycomeandgo
4 weeks ago
I see that even the thought of my having bought Halo in the low 30’s upsets you. Tell you what: don’t worry about it, not good for your health. Be happy instead about what you call my “doom and gloom”, which in your mind will be of great benefit to you. Thank me. You used to thank those who were not sufficiently gung-ho, and informed them that you are going to use your inexhaustible funds to buy the shares they would sell. Notice also I am not quoting you, don’t go postal about words I use without attributing them to you. Bad for your health, like I said. It is my impression that when others express doubts, they are “doom and gloom” people. When you indict management it is completely warranted, constructive and an inducement for management to do better. Halozyme’s price is not where I thought it would be by now. My hopes for the stock have changed. Call that whatever you want, it changes nothing. Where I buy and sell the few share that I do, does not make you better or worse off. If you think I am lying, gloat with a contented grin and maintain a superior silence. Like I said, Happy Easter.
biotechinvestor1
4 weeks ago
Yeah, right! We all believe you. Would you please share to the date of your post when you indicated you were buying some in “low 30’s”? BTW, a retrospective post of saying you bought in 30’s when the stock was already hire would not count.
My prediction of triple digits was incorrect. I own it. It was predicated on three new deals, one of which was supposed to be a major innovation with high-volume auto injector.
This is exactly why I am critical of Halo’s management. They did not deliver on what they projected. You don’t seem to be able to process that an investor can be simultaneously expecting more of a management and yet think that the underlying technology is of a greater value than the market gives it. This is exactly why halo was cheap in low 30’s. The permabears were predicting it was headed to 20’s. It did not.
My point in many of my posts has been that even without new deals, halo was and is cheap. It won’t go to 100’s without new deals, but it can easily reach 50’s and 60’s with existing programs based on it’s PEG , PE ratios, growing profit margin and EBITA.
easycomeandgo
4 weeks ago
Hehe. In my gloom and doom I bought at the amazing low 30’s and I so posted at the time. I intended to sell half at around 45. That was not to be, I sold half around 40. I also posted that at the time. I still have half, but my confidence is waning due to my doom and gloom which virtually guarantees a bright new day, by your theorem. By the way, how is that surge to triple digits within a matter of months you forecast more than a year ago coming along? You recently noted that we have a positive DeBarre indicator. Have you made peace in your own mind with the CEO? The IR person, too? I still have some shares and am anxious to benefit. Happy Easter.
PS. I am still absorbing the secrets of how not the make money, which you revealed to me.
easycomeandgo
4 weeks ago
It would surprise me if Halozyme management did not leave any room for positive surprises. In that, too, I don’t think I am alone or possess some unique grasp of things.
In general, some vague malaise has got hold of this stock, some foreboding… It is as if Halozyme’s time on top of the hill has come and gone, new know-how and fading patent exclusivity is bringing in new and competent entrants. This is certainly obvious with injectors, (with which Halozyme shot itself in the foot, IMO) but also appears with the emergence of other, alternate modes of subcutaneous delivery. I fear the market doubt is systemic. The argument that new technology is early in its development cycle does not seem successful. There may be some doubt about Halozyme‘s continuing in-house research prowess, or ability to substitute it with acquisition.